Tacrolimus
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
May 1, 2008 → Aug 1, 2009
NCT ID
NCT01224418About Tacrolimus
Tacrolimus is a approved stage product being developed by Astellas Pharma for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01224418. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189761 | Phase 2 | Completed |
| NCT00293930 | Phase 3 | Completed |
| NCT00189787 | Phase 2 | Completed |
| NCT00189722 | Phase 2 | Completed |
| NCT03465969 | Approved | Completed |
| NCT02555787 | Pre-clinical | Completed |
| NCT02147938 | Pre-clinical | Completed |
| NCT02143479 | Pre-clinical | Completed |
| NCT02159651 | Pre-clinical | Completed |
| NCT02057484 | Pre-clinical | Completed |
| NCT02377609 | Pre-clinical | Terminated |
| NCT01745159 | Approved | Completed |
| NCT01511003 | Approved | Completed |
| NCT01316133 | Approved | Terminated |
| NCT01410162 | Approved | Completed |
| NCT02963103 | Approved | Terminated |
| NCT01224041 | Approved | Completed |
| NCT01224418 | Approved | Completed |
| NCT00504348 | Phase 2/3 | Completed |
| NCT01410747 | Pre-clinical | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis